European Lung Cancer Congress | Conference

Dr. Garassino on QoL Findings from the FLAURA Study in NSCLC

April 12th 2018

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.

Alectinib Edge Over Crizotinib Supported by Patient-Reported Outcomes

April 12th 2018

In findings consistent with earlier results on efficacy and adverse events reported for the phase III ALEX trial, investigators announced superior patient-reported outcomes for the next-generation tyrosine kinase inhibitor alectinib versus the standard of care TKI inhibitor crizotinib in ALK-positive non–small cell lung cancer.

Frontline Atezolizumab Combo Emerges as Potential New Standard in NSCLC

April 12th 2018

The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.

Atezolizumab Shines in Long-term POPLAR Findings

April 12th 2018

Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.

Dr. Henricus de Koning on Screening in NSCLC

August 19th 2016

Dr. Baas on Next Steps in the Treatment of Mesothelioma

August 19th 2016

Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

Dr. Nir Peled on Next-Generation Sequencing in Lung Cancer

August 2nd 2016

Dr. Keith Kerr on Selecting Patients for Immunotherapy in Lung Cancer

July 6th 2016

Dr. Keith Keer on PD-L1 in Lung Cancer

May 26th 2016

​Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.

Dr. Fred Hirsch on Next Steps for Necitumumab in NSCLC

April 19th 2016

Fred R. Hirsch, MD, PhD, professor of medicine and pathology, University of Colorado Cancer Center, CEO, International Association for the Study of Lung Cancer (IASLC), discusses necitumumab for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC).

Dr. Normanno on Using Circulating Tumor DNA for EGFR Detection

April 16th 2016

Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).

EGFR Testing Strategies Evolving for NSCLC

April 16th 2016

Plasma-based genetic testing can effectively be used to determine whether a tissue biopsy is necessary for EGFR mutation analysis in patients with non–small cell lung cancer.

Dr. Raffaele Califano on Immunotherapy in Small-Cell Lung Cancer

April 16th 2016

Raffaele Califano, MD, consultant in medical oncology at the Christie NHS Foundation Trust and University Hospital of South Manchester, discuses the potential for immunotherapy in small-cell lung cancer (SCLC).

Higher Cytokine Levels Improve Nivolumab Efficacy in Squamous NSCLC

April 16th 2016

Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.

Liquid Biopsy Offers Alternative to Predicting Osimertinib Response in NSCLC

April 16th 2016

Plasma genotyping can, in most cases, identify T790M-positivity in non-small cell lung cancer, which gives patients the option of receiving the targeted therapy osimertinib without the need for a tumor biopsy, according Geoffrey R. Oxnard, MD.

Combined Durvalumab/Gefitinib Combo Shows Promise in EGFR-Mutated NSCLC

April 15th 2016

The first analysis of a trial investigating durvalumab in combination with gefitinib (Iressa) showed encouraging anti-tumor activity and tolerability in patients with non–small cell lung cancer and EGFR mutations that were tyrosine-kinase inhibitor-naïve.

Dr. Paz-Ares on Connection of EGFR-Expression and Necitumumab Response in NSCLC

April 15th 2016

Luis Paz-Ares, MD, PhD, Professor of Medicine at Hospital Universitario 12 de Octubre in Madrid, Spain, discusses a subgroup analysis of patients with EGFR-expressing tumors from the SQUIRE trial, a phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone as first-line treatment for patients with stage IV squamous non-small cell lung cancer (NSCLC).

Dr. Suresh Ramalingam on Frontline Osimertinib in EGFR+ NSCLC

April 15th 2016

Suresh Ramalingam, MD, professor of Hematology and Medical Oncology at Emory School of Medicine and deputy director of Winship Cancer Institute, discusses first-line treatment with single-agent osimertinib in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Update Identifies Best Responders to Necitumumab in NSCLC

April 15th 2016

Adding necitumumab to conventional chemotherapy improved outcomes in patients with metastatic squamous non–small cell lung cancer in the phase III SQUIRE trial, but the greatest benefit was derived by patients with EGFR-expressing tumors.

Novel Vaccine Added to Chemotherapy Improves Patient Outcomes in Mesothelioma

April 15th 2016

The first report of results from a phase Ib clinical trial evaluating CRS-207, a live, attenuated, double-deleted Listeria monocytogenes vaccine, in combination with pemetrexed and cisplatin, demonstrated the effectiveness of this approach for patients with malignant pleural mesothelioma.